Skip to main content

Table 2 Associations between pioglitazone use and gastric cancer risk in a population-based nested case–control study

From: Association of thiazolidinediones with gastric cancer in type 2 diabetes mellitus: a population-based case–control study

Variables

Pioglitazone

Cases

Controls

Crude OR

†Adjusted OR

‡Adjusted OR

N = 357

%

N = 1,428

%

Nonuse

332

93.0

1,274

89.2

1.00

1.00

1.00

Any use

25

7.0

154

10.8

0.62*

0.65*

0.93

  Recent use

11

3.1

75

5.3

0.56*

0.54

0.70

  Past use

14

3.9

79

5.5

0.68*

0.77

1.28

Cumulative dosage

 

  < 260 DDDs

15

4.2

75

5.3

0.77

0.78

1.19

  ≥ 260 DDDs

10

2.8

79

5.5

0.49*

0.52

0.70

Cumulative duration

 

  < 1 year

17

4.8

89

6.2

0.73

0.74

1.14

  ≥ 1 year

8

2.2

65

4.6

0.47*

0.51

0.68

  1. †: Multivariate model adjusted for age, sex, peptic ulcer history, ulcer bleeding history, Helicobacter pylori eradication rate, and comorbidities.
  2. ‡: Multivariate model adjusted for age, sex, peptic ulcer history, ulcer bleeding history, Helicobacter pylori eradication rate, comorbidities, and medications.
  3. OR odds ratios, N number.
  4. *P < 0.05.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us